Oxandrolone for the Treatment of Bone Marrow Aplasia in Fanconi Anemia

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate the safety of the drug oxandrolone (a type of androgen steroid) in patients with Fanconi anemia (FA), and to determine if this drug can help in the treatment of bone marrow failure in these patients. Androgen steroids are male hormones that can stimulate the production of red blood cells (the cells which carry oxygen in the blood) and platelets (cells that help blood clot).

Clinical Trial Description

The primary purpose of this study is to evaluate the safety of the drug oxandrolone in patients with Fanconi anemia (FA), and secondarily to determine if this drug can help in the treatment of bone marrow failure in these patients. It is hoped that oxandrolone will have less side effects than oxymetholone, the androgen used most frequently in the short-term treatment of bone marrow failure in FA patients. Subjects will be enrolled for approximately 18 to 30 months (12 - 24 months of treatment and 6 months additional monitoring). The oxandrolone starting dose is 0.04mg/kg/day. Study monitoring includes weekly complete blood counts, monthly serum chemistry labs, quarterly physical examinations including virilization exams and liver ultrasounds. Semi-annually, hand radiographs are obtained for bone maturation and behavioral assessments are conducted to detect any aggressive behavior or mood changes. If no improvement n the subject's blood counts are noted after 4 months of therapy, the dose will be increased to 0.08mg/kg/day for a period of 4 more months. If no improvement is noted after a total of eight months, oxandrolone will be discontinued. If the blood counts show improvement, then the drug will continue for a minimum of twelve months. Subjects may remain on study and receive a total of 24 months of therapy if they have a response in their blood counts without unacceptable side effects. Post-treatment monitoring includes blood work and ultrasound every three months, and hand radiograph at six months. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00243399
Study type	Interventional
Source	Children's Hospital Medical Center, Cincinnati
Contact
Status	Completed
Phase	Phase 1
Start date	July 2004
Completion date	January 2010

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02931071` - Clinical Phase II Trial to Evaluate CD34+ Cells Mobilization and Collection in Patients With Fanconi Anemia for Subsequent Transduction With a Lentiviral Vector Carring FANCA Gene. FANCOSTEM-1	Phase 2
Terminated	`NCT01319851` - Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation	N/A
Recruiting	`NCT00084695` - Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases	Phase 2
Completed	`NCT00000603` - Cord Blood Stem Cell Transplantation Study (COBLT)	Phase 2
Recruiting	`NCT05687474` - Baby Detect : Genomic Newborn Screening
Recruiting	`NCT01146210` - Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia	N/A
Completed	`NCT01082133` - Multicenter Transplant Study for Fanconi Anemia	Phase 2
Completed	`NCT00965666` - Pilot Study of Etanercept (Enbrel) in Children With Fanconi Anemia	Early Phase 1
Terminated	`NCT00290628` - Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer	N/A
Recruiting	`NCT00027274` - Cancer in Inherited Bone Marrow Failure Syndromes
Terminated	`NCT01001598` - Safety and Efficacy Trial of Danazol in Patients With Fanconi Anemia or Dyskeratosis Congenita	Phase 1/Phase 2
Recruiting	`NCT03206086` - Eltrombopag for People With Fanconi Anemia	Phase 2
Recruiting	`NCT03579875` - Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders	Phase 2
Recruiting	`NCT05598515` - Time-restricted Feeding to Reduce Inflammation in Fanconi Anemia	N/A
Active, not recruiting	`NCT03476330` - Quercetin Chemoprevention for Squamous Cell Carcinoma in Patients With Fanconi Anemia	Phase 2
Terminated	`NCT05910853` - Whole Blood Biospecimen Collection for Subjects With Fanconi Anemia
Completed	`NCT03609840` - Study of Thiotepa and TEPA Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
Completed	`NCT00479115` - Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and AMD3100	Phase 1/Phase 2
Completed	`NCT00352976` - TBI Dose De-escalation for Fanconi Anemia	Phase 2/Phase 3
Terminated	`NCT03600909` - A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.